Pharmacokinetic study of STN1014003 ophthalmic solution in healthy male adults

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2051250132

Enrollment

Registered

2025-10-17

Start date

2025-11-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open angle glaucoma (OAG) or Ocular hypertension (OHT)

Interventions

STN1014003 ophthalmic solution , 1 drop once daily for 8days

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Subjects who can comply with scheduled visits and the examination and observation as specified in the clinical study protocol

Exclusion criteria

Exclusion criteria: 1)Subjects have a disease and/or abnormal laboratory value which is considered inappropriate from safety evaluation perspective 2)Subjects who are inappropriate as participants in this study in the opinion of the investigator or sub investigator

Design outcomes

Primary

Measure	Time frame
Plasma pharmacokinetics	—

Contacts

Public ContactKayoko Sakamoto

Santen pharmaceutical co.,ltd

clinical@santen.co.jp+81-6-4802-9341

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026